Bausch + Lomb (BLCO) Competitors

Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Do insiders & institutionals believe in ZBH or BLCO?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 0.7% of Zimmer Biomet shares are owned by company insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to ZBH or BLCO?

In the previous week, Zimmer Biomet had 14 more articles in the media than Bausch + Lomb. MarketBeat recorded 16 mentions for Zimmer Biomet and 2 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.05 beat Bausch + Lomb's score of 0.84 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	11 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in ZBH or BLCO?

Zimmer Biomet received 866 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 67.24% of users gave Zimmer Biomet an outperform vote while only 41.77% of users gave Bausch + Lomb an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 899 67.24%	Underperform Votes 438 32.76%
Bausch + Lomb	Outperform Votes 33 41.77%	Underperform Votes 46 58.23%

Is ZBH or BLCO more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Bausch + Lomb's net margin of -7.86%. Zimmer Biomet's return on equity of 12.95% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	14.27%	12.95%	7.55%
Bausch + Lomb	-7.86%	3.17%	1.59%

Which has stronger earnings & valuation, ZBH or BLCO?

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.39B	2.94	$1.02B	$5.26	20.78
Bausch + Lomb	$4.68B	1.46	-$260M	-$1.05	-18.47

Do analysts rate ZBH or BLCO?

Zimmer Biomet currently has a consensus price target of $123.22, suggesting a potential upside of 12.73%. Bausch + Lomb has a consensus price target of $20.91, suggesting a potential upside of 7.83%. Given Zimmer Biomet's higher possible upside, equities analysts clearly believe Zimmer Biomet is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bausch + Lomb	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Which has more volatility & risk, ZBH or BLCO?

Zimmer Biomet has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Bausch + Lomb on 16 of the 18 factors compared between the two stocks.